$5.55
+0.56
(+11.22%)▲
Insights on Sophia Genetics Sa
Revenue is down for the last 2 quarters, 17.04M → 15.77M (in $), with an average decrease of 7.4% per quarter
Netprofit is up for the last 2 quarters, -24.06M → -13.70M (in $), with an average increase of 75.6% per quarter
In the last 1 year, Healthequity Inc has given 37.1% return, outperforming this stock by 11.8%
11.53%
Downside
Day's Volatility :12.79%
Upside
1.42%
61.62%
Downside
52 Weeks Volatility :71.1%
Upside
24.69%
Period | Sophia Genetics Sa | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.25% | -1.0% | 0.0% |
6 Months | 33.73% | 9.6% | 0.0% |
1 Year | 32.78% | 11.0% | 0.0% |
3 Years | -66.89% | 18.5% | -22.6% |
Market Capitalization | 323.8M |
Book Value | $2.03 |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 8.67 |
Profit Margin | -113.71% |
Operating Margin TTM | -118.87% |
Return On Assets TTM | -22.51% |
Return On Equity TTM | -46.03% |
Revenue TTM | 64.2M |
Revenue Per Share TTM | 0.99 |
Quarterly Revenue Growth YOY | 13.0% |
Gross Profit TTM | 31.3M |
EBITDA | -72.2M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.93 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 56.22%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 25.4M | - |
Net Income | -33.8M | - |
Net Profit Margin | -133.23% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 28.4M | ↑ 11.98% |
Net Income | -39.3M | ↑ 16.42% |
Net Profit Margin | -138.52% | ↓ 5.29% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 40.5M | ↑ 42.43% |
Net Income | -73.7M | ↑ 87.28% |
Net Profit Margin | -182.14% | ↓ 43.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 47.6M | ↑ 17.58% |
Net Income | -87.4M | ↑ 18.7% |
Net Profit Margin | -183.87% | ↓ 1.73% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 62.4M | ↑ 31.14% |
Net Income | -79.0M | ↓ 9.68% |
Net Profit Margin | -126.63% | ↑ 57.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.4M | ↑ 14.9% |
Net Income | -14.0M | ↓ 40.06% |
Net Profit Margin | -104.39% | ↑ 95.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.0M | ↑ 4.35% |
Net Income | -19.7M | ↑ 41.01% |
Net Profit Margin | -141.06% | ↓ 36.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.1M | ↑ 7.79% |
Net Income | -21.4M | ↑ 8.61% |
Net Profit Margin | -142.13% | ↓ 1.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.3M | ↑ 8.3% |
Net Income | -13.8M | ↓ 35.39% |
Net Profit Margin | -84.79% | ↑ 57.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.0M | ↑ 4.57% |
Net Income | -24.1M | ↑ 74.05% |
Net Profit Margin | -141.14% | ↓ 56.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 15.8M | ↓ 7.44% |
Net Income | -13.7M | ↓ 43.04% |
Net Profit Margin | -86.85% | ↑ 54.29% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 76.6M | - |
Total Liabilities | 21.8M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 51.7M | ↓ 32.58% |
Total Liabilities | 29.4M | ↑ 34.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 132.1M | ↑ 155.76% |
Total Liabilities | 31.6M | ↑ 7.49% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 320.2M | ↑ 142.34% |
Total Liabilities | 44.8M | ↑ 41.66% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 243.8M | ↓ 23.84% |
Total Liabilities | 43.7M | ↓ 2.38% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 206.2M | ↓ 15.45% |
Total Liabilities | 54.7M | ↑ 25.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 243.8M | ↓ 2.69% |
Total Liabilities | 43.7M | ↓ 2.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 232.1M | ↓ 4.83% |
Total Liabilities | 47.1M | ↑ 7.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 223.2M | ↓ 3.82% |
Total Liabilities | 51.5M | ↑ 9.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 205.9M | ↓ 7.77% |
Total Liabilities | 47.4M | ↓ 7.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 206.2M | ↑ 0.15% |
Total Liabilities | 54.7M | ↑ 15.4% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 180.3M | ↓ 12.56% |
Total Liabilities | 48.0M | ↓ 12.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.7M | - |
Investing Cash Flow | -3.0M | - |
Financing Cash Flow | -1.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.7M | ↑ 0.16% |
Investing Cash Flow | -24.3M | ↑ 701.95% |
Financing Cash Flow | 107.0M | ↓ 10563.83% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -57.9M | ↑ 82.6% |
Investing Cash Flow | -56.9M | ↑ 134.07% |
Financing Cash Flow | 237.8M | ↑ 122.12% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.1M | ↑ 20.98% |
Investing Cash Flow | 42.0M | ↓ 173.72% |
Financing Cash Flow | -1.6M | ↓ 100.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↓ 54.74% |
Investing Cash Flow | 12.1M | ↑ 287.55% |
Financing Cash Flow | -580.0K | ↓ 28.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.8M | ↑ 43.18% |
Investing Cash Flow | -1.8M | ↓ 114.96% |
Financing Cash Flow | -935.0K | ↑ 61.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↓ 30.19% |
Investing Cash Flow | -1.8M | ↑ 0.0% |
Financing Cash Flow | -619.0K | ↓ 33.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↑ 17.88% |
Investing Cash Flow | -2.1M | ↑ 15.69% |
Financing Cash Flow | -757.0K | ↑ 22.29% |
Sell
Neutral
Buy
Sophia Genetics Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sophia Genetics Sa | 9.9% | 33.73% | 32.78% | -66.89% | -66.89% |
Solventum Corp | -11.81% | -17.44% | -17.44% | -17.44% | -17.44% |
Veeva Systems Inc. | -15.62% | -4.25% | -11.39% | -40.54% | 10.17% |
Ge Healthcare Technologies Inc. | -3.32% | 11.22% | -4.15% | 27.54% | 27.54% |
Healthequity Inc | 2.46% | 17.61% | 38.04% | 0.15% | 23.92% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sophia Genetics Sa | NA | NA | NA | -0.93 | -0.46 | -0.23 | NA | 2.03 |
Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
Veeva Systems Inc. | 51.25 | 51.25 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 22.68 | 22.68 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
Healthequity Inc | 127.63 | 127.63 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sophia Genetics Sa | Buy | $323.8M | -66.89% | NA | -113.71% |
Solventum Corp | Hold | $10.8B | -17.44% | NA | 15.73% |
Veeva Systems Inc. | Buy | $28.2B | 10.17% | 51.25 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $35.6B | 27.54% | 22.68 | 8.05% |
Healthequity Inc | Buy | $7.1B | 23.92% | 127.63 | 5.57% |
Generation Investment Management LLP
Banque Pictet & Cie SA
Credit Suisse First Boston (CSFB)
Millennium Management LLC
Alta Wealth Advisors LLC
Principal Financial Group Inc
sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based
Organization | Sophia Genetics Sa |
Employees | 430 |
CEO | Dr. Jurgi Camblong M.B.A., Ph.D. |
Industry | Technology |